[News] The Investigator Meeting for the Phase II Clinical Trial of KJ103 (Ricefidase) for Anti-GBM Disease Successfully Concludes

On June 29, 2024, Shanghai Bao Pharmaceuticals Co., Ltd. successfully held the Investigator Meeting for the Phase II Clinical Trial of KJ103 for treating anti-glomerular basement membrane (GBM) disease in Beijing, marking the official launch of the Phase II clinical trial. The leading institution for the research is Professor Zhao Minghui, Director of the Kidney Disease Research Institute at Peking University First Hospital, who also serves as the principal investigator (PI).
The meeting was conducted both offline and online, hosted by Dr. Liu Yanjun, Chairman of Shanghai Bao Pharmaceuticals Co., Ltd. Professor Zhao Minghui, as the PI for the Phase II trial, delivered the opening speech, stating: “I am honored to serve as the principal investigator for the Phase II clinical trial of KJ103. Anti-GBM disease is one of the most severe glomerular diseases, presenting as type I crescentic nephritis. The disease progresses rapidly and can lead to kidney failure and diffuse alveolar hemorrhage, which can result in suffocation and pose a life-threatening risk. At the time of diagnosis, 80% of patients are already in uremia. KJ103 is the first new drug in China specifically targeting anti-GBM disease. It is an excellent treatment that fills a significant gap in clinical treatments for this condition. I wish the Phase II clinical trial of KJ103 great success.”
Professor Wang Yu from the First Affiliated Hospital of Nanchang University and Professor Han Min from Tongji Hospital Tongji Medical College of HUST both emphasized: “Anti-GBM disease is rare, severe, and has a poor prognosis. The Phase II clinical trial of KJ103 will be a crucial step in advancing the field of anti-GBM disease treatment. The successful development of KJ103 will undoubtedly provide a faster and more effective treatment for this condition. Our hospital will fully cooperate to ensure high-quality clinical research, promote the significant progress of domestic innovative drugs, and contribute to the early market availability of KJ103.”
The atmosphere at the meeting was lively, with experts and scholars from all over the country gathering together. Dr. Zhu Zhen, Clinical Director of Shanghai Bao Pharmaceuticals Co., Ltd., provided an overview of the development background and history of KJ103. Following that, Dr. Yao Wenqi, Medical Director of SDM Bioservices Inc., introduced the disease mechani**s, diagnostic methods, treatment strategies, and design and operation of the Phase II clinical trial protocol. The experts held thorough and in-depth discussions on the trial protocol, offering valuable suggestions that laid a solid foundation for the scientific and standardized implementation of the Phase II clinical study.
In his concluding remarks, Dr. Liu Yanjun expressed sincere gratitude to the experts who traveled from across the country to attend the Phase II Investigator Meeting for KJ103. He also thanked the experts for their high recognition of KJ103. BaoPharma will continue its efforts to meet the urgent needs of patients and steadily advance the clinical research plans for multiple product lines, providing more comprehensive treatment options for patients with rare autoimmune diseases and enhancing the treatment outcomes and quality of life for autoimmune patients.